GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » 14-Day RSI

CERo Therapeutics Holdings (CERo Therapeutics Holdings) 14-Day RSI : 31.51 (As of May. 12, 2024)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-12), CERo Therapeutics Holdings's 14-Day RSI is 31.51.

The industry rank for CERo Therapeutics Holdings's 14-Day RSI or its related term are showing as below:

CERO's 14-Day RSI is ranked better than
92.76% of 1575 companies
in the Biotechnology industry
Industry Median: 47.39 vs CERO: 31.51

Competitive Comparison of CERo Therapeutics Holdings's 14-Day RSI

For the Biotechnology subindustry, CERo Therapeutics Holdings's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's 14-Day RSI falls into.



CERo Therapeutics Holdings  (NAS:CERO) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CERo Therapeutics Holdings  (NAS:CERO) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


CERo Therapeutics Holdings 14-Day RSI Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines